Guggenheim today maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a price target of $69.00. Analyst Louise Chen ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE